Wilson’s Disease, Etiology and Treatment Wilson disease
International Journal of Medical Toxicology and Forensic Medicine,
Vol. 15 No. 1 (2025),
12 February 2025
https://doi.org/10.32598/ijmtfm.v15i1.45885
Abstract
Background: Wilson’s disease is a chronic, gradually developed disease. Its concern is as an autosomal recessive inherited metabolic disorder. The deposition of copper in many organs, such as the liver, eyes, kidneys, and basal ganglia in the brain is the main cause of this disease.
Case Presentation: A 13-year-old male patient was admitted to the Children’s Department in Al-Kadhimae Hospital, Iraq with chief complaints of vomiting, abdominal pain, pallor, icterus, fever, and chest complaints. The laboratory data showed elevated levels of total bilirubin, alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase and reduced levels of globulin (α2 and β), ceruloplasmin, and serum copper. Additionally, high urine copper was reported. After that the patient was diagnosed with Wilson disease and treated with D-penicillamine drug (copper chelation) and zinc acetate tablet.
Conclusion: Wilson’s disease is a metabolic error of copper, if undetected and untreated immediately, it causes declining in the function of many organs, such as the liver and brain.
- Wilson’s disease
- Copper
- Plasma Ceruloplasmin
- Penicillamine
How to Cite
References
Meenakshi-Sundaram S, Mahadevan A, Taly AB, Arunodaya GR, Swamy HS, Shankar SK. Wilson’s disease: A clinic neuropathological autopsy study. Journal of Clinical Neuroscience. 2008; 15(4):409-17. [DOI:10.1016/j.jocn.2006.07.017] [PMID]
Rada FH. Impact of Osteoprotegerin and RANKL on Non-ST- segment Elevation Myocardial Infarction. International Journal of Nutrition, Pharmacology, Neurological Diseases. 2021; 1193):206-10. [Link]
Rada FH. Effect of angiotensin II receptor blocker treatment on adipokine of corpulence. Biomedical and Pharmacology Journal. 2020; 13(2) 957-63. [DOI:10.13005/bpj/1964]
Golovanova EV, Lazebnik LB, Konev YV, Shaposhnikova NA. [Wilson's Disease (Hepatolenticular degeneration, dystrophia hepatocerebralis) diagnosis, treatment and dispensary observation. guidelines were approved by the Xv Gastroenterological scientific society of Russia in 2015] (Russian)]. Experimental & Clinical Gastroenterology. 2015; 7(7):108-11. [PMID]
Hoffmann GF, Engelmann G: Liver Disease. In: Hoffmann G, Zschocke J, Nyhan W, editors. Inherited metabolic diseases. New York: Springer; 2010. [DOI:10.1007/978-3-540-74723-9]
Semba R. Inborn Errors of Metabolism. In: Semba R, editor. Handbook of Nutrition and Ophthalmology. New Jersey: Humana Press; 2007. [DOI:10.1007/978-1-59259-979-0]
European Association for Study of Liver. EASL clinical practice guidelines: Wilson’s disease. Journal of Hepatology. 2012; 56(3):671-85. [DOI:10.1016/j.jhep.2011.11.007] [PMID]
Czlonkowska A, Litwin T, Dusek P, Ferenci P, Lutsenko S, Medici V, et al. Wilson disease. Nature Reviews. Disease primers. 2018; 4(1):21. [DOI:10.1038/s41572-018-0018-3] [PMID]
Supriya R, Kamba BM, Yarraguntla K, Haritha G, Chigurupati D. A Case Report on Wilson’s Disease. Journal of Young Pharmacists. 2023; 15(2):384-6. [DOI:10.5530/jyp.2023.15.52]
Aggarwal A, Bhatt M. The pragmatic treatment of Wilson’s disease. Movement Disorders Clinical Practice. 2014;1(1):14-23. [DOI:10.1002/mdc3.12003] [PMID]
Nagral A, Sarma MS, Matthai J, Kukkle PL, Devarbhavi H, Sinha S, et al. Wilson’s Disease: Clinical practice guidelines of the Indian National Association for Study of the Liver, the Indian Society of Pediatric Gastroenterology, Hepatology and Nutrition, and the Movement Disorders Society of India. Journal of Clinical and Experimental Hepatology. 2019; 9(1):74-98. [DOI:10.1016/j.jceh.2018.08.009] [PMID]
Roberts EA. Update on the diagnosis and management of Wilson Disease. Current Gastroenterology Reports. 2018; 20(12):56. [DOI:10.1007/s11894-018-0660-7] [PMID]
Bandmann O, Weiss KH, Kaler SG. Wilson’s disease and other neurological copper disorders. The Lancet. Neurology. 2015; 14(1):103-13. [DOI:10.1016/S1474-4422(14)70190-5] [PMID]
Mohammed AK, Najeeb AA, Tawfeeq WF. Wilson’s Disease; Clinical presentations among patients attending gastroenterology clinic/ Baghdad Teaching Hospital. Al-Kindy College Medical Journal .2013; 9 (1):117-25. [Link]
Merle U, Stremmel W. Wilson’s Disease. In: Friedman SL, editor. Clinical Hepatology. Berlin: Springer; 2010.[DOI:10.1007/978-3-642-04519-6_27]
Park K: Principles of Epidemiology and Epidemiologic Methods. In:Park K, eds. Park’s textbook of preventive and social medicine. 16th ed. BanarisidasBhanot Publishers: India. 2001;27:56-8.
Lorincz M. Neurologic Wilson’s disease. Annals of the New York Academy of Sciences. 2010, 1184:173-87. [DOI:10.1111/j.1749-6632.2009.05109.x] [PMID]
Mak CM, Lam CW. Diagnosis of Wilson’s disease: A comprehensive review. Critical Reviews in Clinical Laboratory sciences. 2008; 45(3):263-90. [DOI:10.1080/10408360801991055] [PMID]
Barbosa ER, Machado AA, Cançado EL, Deguti MM, Scaff M. Wilson’s disease: A case report and a historical review. Arquivos de Neuro-Psiquiatria. 2009; 67(2B):539-43. [DOI:10.1590/S0004-282X2009000300036] [PMID]
Seetharaman J, Sarma MS. Chelation therapy in liver diseases of childhood: Current status and response. World Journal of Hepatology.2021; 13(11):1552-67. [DOI:10.4254/wjh.v13.i11.1552] [PMID]
Lheureux P, Penaloza A, Gris M. Pyridoxine in clinical toxicology: A review. European Journal of Emergency Medicine. 2005; 12(2):78-85. [DOI:10.1097/00063110-200504000-00007] [PMID]
Kumar V, Singh AP, Wheeler N, Galindo CL, Kim JJ. Safety profile of D-penicillamine: A comprehensive pharmacovigilance analysis by FDA adverse event reporting system. Expert Opinion on Drug Safety. 2021; 20(11):1443-50. [DOI:10.1080/14740338.2021.1956460] [PMID]
Dahlman T, Hartvig P, Löfholm M, Nordlinder H, Lööf L, Westermark K. Long-term treatment of Wilson’s disease with triethylene tetramine dihydrochloride (trientine). QJM: Monthly Journal of the Association of Physicians. 1995; 88(9):609-16. [PMID]
Schilsky ML. Treatment of Wilson’s disease: What are the relative roles of penicillamine, trientine, and zinc supplementation. Current Gastroenterology Reports. 2001; 3(1):54-9.[DOI:10.1007/s11894-001-0041-4] [PMID]
Medici V, Trevisan CP, D'Incà R, Barollo M, Zancan L, Fagiuoli S, et al. Diagnosis and management of Wilson’s Disease: Results of a single center experience. Journal of Clinical Gastroenterology. 2006; 40(10):936-41. [DOI:10.1097/01.mcg.0000225670.91722.59] [PMID]
Santiago R, Gottrand F, Debray D, Bridoux L, Lachaux A, Morali A, et al. Zinc therapy for Wilson Disease in children in French Pediatric Centers. Journal of Pediatric Gastroenterology and Nutrition. 2015; 61(6):613-8. [DOI:10.1097/MPG.0000000000000926] [PMID]
- Abstract Viewed: 80 times
- pdf Downloaded: 64 times